Pediatric Patients

If validated, metabolite patterns could help predict which children will reach remission on vedolizumab, potentially guiding treatment choices and avoiding ineffective therapy.

Mirikizumab is being tested specifically in children with moderate-to-severe Crohn’s disease; successful results could expand treatment options for pediatric IBD. The study measures both symptom-based and endoscopic...

This trial is testing whether continued mirikizumab treatment helps children and teens with ulcerative colitis or Crohn’s disease achieve and maintain remission over the long term. Results could expand pediatric...

A structured ERP adapted for children could shorten hospital stays and improve recovery after pediatric GI surgery; this trial tested both clinical effectiveness and real-world implementation across many pediatric...

An extra mRNA COVID-19 vaccine dose produced only modest increases in antibody and T‑cell responses in immunosuppressed children (including those with IBD), so vaccine protection may still be lower than in healthy...

If validated, a simple ultrasound-based score could reduce the need for invasive endoscopy to monitor disease activity in children with ulcerative colitis. Noninvasive monitoring is especially valuable in pediatrics.

Oral signs such as persistent lip swelling can be an early presentation of Crohn’s disease in adolescents and may prompt testing that leads to earlier diagnosis and treatment.

Patients on anti-TNF biologics often seek safe ways to support gut microbial health. This trial tests a prebiotic supplement (2'-FL) for safety and whether it increases beneficial bacteria and butyrate in young people...

Endoscopy comfort and sedation differ between pediatric and adult settings, and worse adult experiences could deter young adults from needed surveillance or care. Addressing sedation choice, communication, and provider...

Adolescents with IBD often experience abdominal pain that affects daily life. This study suggests psychological resilience — especially optimism and mindfulness — is linked with less pain, pointing to nonpharmacologic...

This paper suggests that epithelial barrier structure and function may be altered in very early onset pediatric IBD. That could help researchers study disease mechanisms and eventually guide targeted therapies for...

This study compares two commonly used anti‑TNF biologics in children with Crohn’s disease using real‑world prospective data, so its findings are directly relevant to treatment choice, expectations for 1‑year remission,...

UGI involvement in children with IBD was common and linked to a more severe disease course — lower remission rates and more frequent need for biologic therapy — which could affect monitoring and treatment planning.

Shorter height at IBD diagnosis was more common in Hispanic/Latino children and those without private insurance, which may reflect inequities in timely diagnosis and access to nutrition and care—issues that can affect...

A Phase 3 study is testing whether oral tofacitinib can induce and maintain remission in children with moderate-to-severe ulcerative colitis — a key step before pediatric regulatory approvals and wider clinical use.

This study provides region-specific pediatric IBD data from the Philippines, highlighting prevalence of very-early-onset disease, perianal involvement in Crohn's, and factors (diagnostic delay, wasting, pancolitis)...

Faster remission can reduce symptoms, school disruption, and steroid exposure for children with IBD. If earlier infliximab level checks reliably speed remission, clinicians could adjust dosing sooner to improve outcomes.

SpA is a frequent but underrecognized extraintestinal manifestation in people with IBD; validated screening tools can help identify patients who need rheumatology evaluation. Earlier detection may address joint symptoms...

The oral microbiome in children with Crohn's disease appears to reflect disease severity and changes with treatment, suggesting a potential noninvasive biomarker for monitoring response to nutritional therapies like CDED...

This large pediatric registry study suggests children starting infliximab biosimilars have similar 12‑month clinical outcomes and treatment durability as those starting the originator drug — reassuring for patients and...

This trial could provide long-term safety data on guselkumab for children with moderate-to-severe Crohn's disease or ulcerative colitis and offers continued access to the drug for participants from earlier pediatric...

The study explores engineering HSPCs to induce IL-10–mediated, antigen-specific regulatory responses, which could lead to new cell-based strategies for children with refractory IBD who do not respond to current...

Fatigue is a common, impactful symptom in pediatric and young-adult IBD but is poorly defined and measured, limiting the ability to design age-appropriate supports. This review highlights gaps that affect patients' daily...

The trial tests ustekinumab dosing, safety, and pharmacokinetics specifically in children with moderate–severe Crohn’s — information that can affect pediatric treatment options and dosing guidance once results are...

Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...

The paper suggests that HRQoL and family functioning may be similar across disease types and common treatment approaches in children with IBD, but emotional health and parental worry remain areas needing attention.

Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...

Children with autoimmune gastrointestinal diseases can have impaired bone health.

The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...

The coexistence of Peutz-Jeghers syndrome and Crohn's disease is exceptionally rare, and both conditions carry increased cancer risk. Patients, families, and clinicians need to know that there is little evidence to guide...

IBD can cause inflammation outside the gut; this report shows rare eye, facial muscle, and salivary gland involvement occurring at the time of ulcerative colitis diagnosis in a child, which could affect evaluation and...

Diagnostic delays can mean a child with Crohn's disease doesn't get timely treatment. This report shows weight loss in young patients—especially girls—can be mistakenly labeled an eating disorder, so awareness and...

The report suggests tofacitinib (a JAK inhibitor), alone or combined with ustekinumab, could be an effective option for some infants with treatment-refractory IOIBD — a population with few evidence-based alternatives. If...

Integrated joint appointments could make it easier for children with IBD and their families to get coordinated care for symptoms, nutrition, and mental health in a single visit, which may improve access and reduce stigma...

VEOIBD often has a strong genetic component and different clinical needs than adult IBD; this study shows genetic findings and treatment challenges in a Middle East pediatric center, which may affect diagnosis and access...

If reliable, an earlier day‑3 PUCAI cutoff could help identify children with flare‑related ASUC who are unlikely to respond to IV steroids and who may benefit from earlier planning for second‑line therapy rather than...

A simple blood ratio measured before surgery (LCR) may help predict which children with UC are at higher risk of surgical site infection after IPAA, potentially guiding preoperative care.

Finding monogenic causes in infants with congenital diarrheas or VEOIBD can directly affect diagnosis, genetic counseling, and management. Populations with higher consanguinity may have higher diagnostic yields for...

Children with IBD commonly experience emotional and social challenges; residential camps appear to improve quality of life, confidence, disease knowledge, and reduce isolation, making them relevant as a supportive,...

Reactive TDM can help determine why a child with Crohn's disease is losing response to adalimumab and guide whether to escalate dose or switch biologics, which affects short-term management decisions.

An ELANE mutation causing severe congenital neutropenia can present with neutropenic enterocolitis that mimics ulcerative colitis. Recognizing neutropenia and pursuing genetic testing can prevent misdiagnosis and change...

This trial explores whether oral ozanimod can induce and maintain remission in children and adolescents with moderate to severe ulcerative colitis who have not responded to standard therapies. Pediatric-specific evidence...

Transition from pediatric to adult IBD care is a high-risk period; structured programs and better communication can improve adherence and reduce relapse and hospitalization risk for young people with IBD.

Dietary therapy (CDED + PEN) was associated with longer remission when families adhered well; since adherence varies, support from a dietitian matters for keeping children in remission.

Subcutaneous infliximab could offer children with IBD a more convenient dosing route with higher, steadier drug levels while maintaining remission. Insurance and labeling barriers affected access in this US cohort.

Children with IBD can have persistent gut–brain interaction symptoms even when inflammation is quiescent; these symptoms are linked with worse quality of life and higher anxiety. Recognizing DGBI-like symptoms may help...

The study investigates how components of exclusive enteral nutrition (EEN), particularly transforming growth factor‑β (TGF‑β), may help restore intestinal barrier function after colitis. That could help explain why EEN...

A cross‑trust histopathology MDT helped reclassify diagnoses in a substantial proportion of discussed paediatric IBD cases and occasionally changed management or transition planning, which could affect treatment...